cd-47

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

Letaplimab (IBI-188) is a humanized IgG4 class antibody targeting CD47 and is often used in combination with azacitidine for the treatment of primary diagnosis of intermediate- to high-risk myelodysplastic syndromes.

Anti-Human CD47 Antibody (B6H12, humanized) is a humanized anti-CD47 antibody developed based on the classical murine B6H12 clone and designed to recognize human CD47. Compared with the original murine antibody, this humanized antibody may reduce the immunogenicity risk associated with murine antibodies and is suitable for CD47-related antibody drug development and functional research.

Anti-Human CD47 Antibody (B6H12) is a monoclonal inhibitory antibody that targets human CD47 and is suitable for use in life science research.

Anti-CD47 Antibody (CO-1) is an antibody targeting CD47 and can be used for oncology research.

Anti-CD47 Antibody (1F80) is an antibody targeting CD47 and can be used for immunology research.

Anti-Rat CD47 Antibody (OX-101) is an antibody targeting Rat CD47 and can be used for immunology research.

Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an IgG1 monoclonal antibody specifically directed against mouse, rat, and human CD47/IAP. It effectively blocks CD47-mediated signaling to enhance macrophage phagocytic activity, promote immune cell infiltration into tissues, potentially interfere with wound healing processes, and support experimental investigations in oncology and inflammatory disease models, including but not limited to breast cancer research and studies of intestinal mucosal repair mechanisms.

Anti-CD47 (A4) antibody is a kind of antibody that can be used for Blocking, functional assays, FC and other related research.

Anti-CD47 (h4C1) antibody is a kind of antibody that can be used for activity assays, functional studies, binding affinity analysis, and other applications, serving as an essential tool in biological research.

Anti-CD47 Antibody (VxP037) is a kind of antibody that can be used for blocking and other related research.

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.

HX009 is a bispecific antibody targeting PD-1 and CD47 (EC50=0.05 nM/0.24 nM). It binds and blocks PD-1 and CD47, selectively localizes to the tumor microenvironment, and reduces hematotoxicity. It can be used to study non-Hodgkin lymphoma (NHL).

Tetracosanoic-D47 Acid (Standard) is a reference standard of Tetracosanoic-D47 Acid intended for quantitative analysis, quality control, and related biochemical research applications.

Cys-PKHB1 (Cys-txCD47) is a polypeptide consisting of a cysteine (Cys) residue coupled with PKHB1, which is a CD47 agonist peptide that acts as a thrombospondin-1 peptide mimetic with anti-tumor properties. In breast cancer cells, PKHB1 induces mitochondrial changes, ROS production, intracellular Ca+ accumulation, and calcium-dependent cell death. Additionally, PKHB1 activates the immune system by inducing immunogenic cell death in breast cancer cells.

Cys-PKHB1 (Cys-txCD47) TFA is a polypeptide consisting of a cysteine (Cys) residue conjugated with PKHB1, which is a CD47 agonist peptide that mimics the anti-tumor effects of thrombospondin-1 peptides. In breast cancer cells, PKHB1 induces mitochondrial changes, ROS production, intracellular accumulation of Ca+, and calcium-dependent cell death. Furthermore, PKHB1 activates the immune system through immunogenic cell death of breast cancer cells.